Talk:Pixantrone
Add topic | This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
Impact
[edit]The last section recently added with comments from individuals, only backed up with press-releases is more close to a commercial statement than encyclopedic style. Additionally it goes against WP:MEDRS and WP:MEDMOS. I am going to procceed to eliminate them. Bests.--Garrondo (talk) 13:40, 18 May 2009 (UTC)
Table
[edit]I have eliminated the table per WP:MEDMOS, audience: it is written for professionals. It contains statistical values of efficacy (p values), number of subjects, which are of no use for a general audience. Bests. --Garrondo (talk) 13:50, 18 May 2009 (UTC)
Comments on mitoxantrone and MS
[edit]Inclusion of efficacy of mitoxantrone as a reason for the efficacy of pixantrone in the same disease is original research unless backed up by specific reliable sources which state it.Removed. Bests. --Garrondo (talk) 13:58, 18 May 2009 (UTC)
Clinical trial leads to full EU approval for some nHL
[edit]Clinical trial leads to full EU approval for some nHL - Rod57 (talk) 11:14, 23 June 2019 (UTC)
Could we add a mechanism of action section
[edit]Mechanism of action is mentioned in History (may vary by indication as in Research). Could be helpful to highlight in own section as in many other drug articles ?
Would it be fair to call it a chemotherapy since/if it acts by preventing cell division generally ? - Rod57 (talk) 11:19, 23 June 2019 (UTC)